Change of serum level of β2-microglobulin in patients with glioma
LI Kai
LI Zhi-qiang
ZHAO Yu-hang
XU Cheng-shi
XIONG Zhong-wei
CHEN Jin-cao
Abstract：Objective To investigate the change of the serum level of β2-microglobulin (β2-MG) in the patients with glioma and its clinical meaning. Methods Serum β2-MG level was measured by latex immunoturbidimetry in 124 patients with gliomas including 9 with WHO grae Ⅰ gliomas, 28 WHO grade Ⅱ, 34 WHO grade Ⅲ, 53 WHO grade Ⅳ 2~3 days before the operation. The paraffin-embedded glioma tissues were used to detect the mutation of isocitrate dehydrogenase 1 (IDH1) by capillary electrophoresis and the methylation of 06-alkylguanuine DNA alkylransferase (MGMT) gene promoter by PCR fluorescence probe. The differences of the serum levels of β2-MG between the patients with IDH1 wild-type and IDH1 mutionbype gliomas, the ones with methylated and non-methylated MGMT gliomas, and the ones with different WHO grades gliomas. Results The serum level of β2-MG was significantly higher in the patients with WHO gradeⅣgliomas than that in the patients with WHO gradeⅠ~Ⅲ gliomas (P<0.05). The serum level of β2-MG was significantly lower in the patients with IDH1 mutant goliomas than in the patients with IDH1 wild-type goliomas (P<0.05). There was insigificantly difference in the serum level of β2-MG between the patients with MGMT methylation goliomas and the patients with MGMT demethylation goliomas (P>0.05). Conclusion The serum level of β2-MG may be the great helpful to differentiating WHO gradeⅣgliomas from other grade gliomas, as well as diffeeretiating IDH1 mutation glioma from wild-type glioma.
Keywords：Gliomasβ2 microglobulinIsocitrate dehydrogenase 106-alkylguanuine DNA alkylransferase
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 159-161 )